Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: Beyond the butterfly

Current Pharmaceutical Design

Volumn 12, Issue 15, 2006, Pages 1857-1865

  Basavapathruni, Aravind ^a   Anderson, Karen S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS drugs; HIV 1 reverse transcriptase; Nonnucleoside

Indexed keywords

1 [(2 HYDROXYETHOXY)METHYL] 6 (PHENYLTHIO)THYMINE; 9 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; ANTIRETROVIRUS AGENT; CAPRAVIRINE; CP 94707; DELAVIRDINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; KM 1; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEFAVIRENZ; STAVUDINE; UC 38; UC 84; UNCLASSIFIED DRUG; ZIDOVUDINE;

CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTI-HIV AGENTS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33646509695     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776873617     Document Type: Review

References (78)

1. Furman PA, Painter GR, Anderson KS. An analysis of the catalytic cycle of HIV-1 reverse transcriptase: opportunities for chemotherapeutic intervention based on enzyme inhibition. Curr Pharm Des 2000; 6: 547-67.
2. De Clercq E. New approaches toward anti-HIV chemotherapy. Journal of Medicinal Chemistry 2005; 48: 1297-313.
3. Sarafianos SG, Das K, Hughes SH, Arnold E. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr Opin Struct Biol 2004; 14: 716-30.
4. Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of nonnucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 2005; 88: 209-31.
5. Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr Opin Pharmacol 2004; 4: 437-46.
6. Balzarini J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem 2004; 4: 921-944.
7. Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-4-4-(1E)-2-cyanoethenyl]- 2,6-dimethylphenyl]amino] -2-pyrimidinyl]amino ]benzonitrile (R278474, rilpivirine). J Med Chem 2005; 48: 1901-9.
8. De Corte BL. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 2005; 48: 1689-96.
9. Baba M, Tanaka H, De Clercq E, Pauwels R, Balzarini J, Schols D, et al. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun 1989; 165: 1375-81.
10. Debyser Z, Pauwels R, Andries K, Desmyter J, Kukla M, Janssen PA, et al. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. Proc Natl Acad Sci USA 1991; 88: 1451-5.
11. Miyasaka T, Tanaka H, Baba M, Hayakawa H, Walker RT, Balzarini J, et al. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxyl]methyl]-6-(phenylthio)thymine. J Med Chem 1989; 32: 2507-9.
12. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990; 343: 470-4.
13. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990; 250: 1411-3.
14. De Clerc QE. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): past, present, and future. Chem Biodivers 2004; 1: 44-64.
15. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996; 271: 1582-6.
16. Sallie R. Replicative Homeostasis: A fundamental mechanism mediating selective viral replication and escape mutation. Virol J 2005; 2: 10.
17. Mellors JW, Dutschman GE, Im GJ, Tramontano E, Winkler SR, Cheng YC. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol Pharmacol 1992; 41: 446-51.
18. Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991; 88: 11241-5.
19. Dueweke TJ, Poppe SM, Romero DL, Swaney SM, So AG, Downey KM, et al . U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1993; 37: 1127-31.
20. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39: 2602-5.
21. Balzarini J, De Clercq E, Carbonez A, Burt V, Kleim JP. Longterm exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses 2000; 16: 517-28.
22. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998; 38: 153-79.
23. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, et al. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol 2001; 312: 795-805.
24. Spence RA, Anderson KS, Johnson KA. HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry 1996; 35: 1054-63.
25. Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47: 2550-60.
26. Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitorcontaining regimen. J Med Virol 2001; 65: 445-8.
27. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001; 75: 4999-5008.
28. Maga G, Amacker M, Ruel N, Hubscher U, Spadari S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J Mol Biol 1997; 274: 738-47.
29. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med 2005; 13: 51-7.
30. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-90.
31. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995; 2: 293-302.
32. Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PA, et al. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol 1995; 2: 407-15.
33. Carroll SS, Olsen DB, Bennett CD, Gotlib L, Graham DJ, Condra JH, et al. Inhibition of HIV-1 reverse transcriptase by pyridinone derivatives. Potency, binding characteristics, and effect of template sequence. J Biol Chem 1993; 268: 276-81.
34. Althaus IW, Chou JJ, Gonzales AJ, Deibel MR, Chou KC, Kezdy FJ, et al. Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J Biol Chem 1993; 268: 6119-24.
35. Frank KB, Noll GJ, Connell EV, Sim IS. Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo [4,5,1-jk]-[1,4]-benzodiazepine-2-(1H)-thione compound, R82150. J Biol Chem 1991; 266: 14232-6.
36. Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schleif WA, Freund KF, et al. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA 1991; 88: 6863-7.
37. Taylor PB, Culp JS, Debouck C, Johnson RK, Patil AD, Woolf DJ, et al . Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors. J Biol Chem 1994; 269: 6325-31.
38. Tramontano E, Cheng YC. HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. Biochem Pharmacol 1992; 43: 1371-6.
39. Fletcher RS, Syed K, Mithani S, Dmitrienko GI, Parniak MA. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme. Biochemistry 1995; 34: 4346-53.
40. Barnard J, Borkow G, Parniak MA. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 1997; 36: 7786-92.
41. Maga G, Ubiali D, Salvetti R, Pregnolato M, Spadari S. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thiosubstituted analog with different enzyme-substrate complexes. Antimicrob Agents Chemother 2000; 44: 1186-94.
42. Johnson KA. Rapid Quench Kinetic Analysis of Polymerases, Adenosinetriphosphatases, and Enzyme Intermediates. Meth Enzymol 1995; 249: 38-61.
43. Johnson KA. Transient State Kinetic Analysis of Enzyme Reaction Pathways. The Enzymes 1992; 20: 1-61.
44. Kati WM, Johnson KA, Jerva LF, Anderson KS. Mechanism and fidelity of HIV reverse transcriptase. J Biol Chem 1992; 267: 25988-97.
45. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995; 267: 988-93.
46. Rittinger K, Divita G, Goody RS. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci USA 1995; 92: 8046-9.
47. Hammer SM, Kessler HA, Saag MS. Issues in combination antiretroviral therapy: a review. J Acquir Immune Defic Syndr 1994; 7(Suppl 2): S24-35; discussion S35-7.
48. De Clercq E. HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses 1992; 8: 119-34.
49. King RW, Klabe RM, Reid CD, Erickson-Viitanen SK. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob Agents Chemother 2002; 46: 1640-6.
50. Borkow G, Arion D, Wainberg MA, Parniak MA. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43: 259-63.
51. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998; 37: 15908-17.
52. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chainterminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1998; 95: 13471-6.
53. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999; 4: 35-43.
54. Meyer PR, Matsuura SE, Schinazi RF, So AG, Scott WA. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob Agents Chemother 2000; 44: 3465-72.
55. Meyer PR, Matsuura SE, Tolun AA, Pfeifer I, So AG, Mellors JW, et al. Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2002; 46: 1540-5.
56. Ray AS, Murakami E, Basavapathruni A, Vaccaro JA, Ulrich D, Chu CK, et al. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 2003; 42: 8831-41.
57. Odriozola L, Cruchaga C, Andreola M, Dolle V, Nguyen CH, Tarrago-Litvak L, et al. Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase Inhibit Phosphorolysis and Resensitize the 3′-Azido-3′-deoxythymidine (AZT)-resistant Polymerase to AZT-5′-triphosphate. J Biol Chem 2003; 278: 42710-42716.
58. Basavapathruni A, Bailey CM, Anderson KS. Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J Biol Chem 2004; 279: 6221-6224.
59. Cruchaga C, Odriozola L, Andreola M, Tarrago-Litvak L, Martinez-Irujo JJ. Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3′-azido-3′-deoxythymidine with nonnucleoside inhibitors. Biochemistry 2005; 44: 3535-46.
60. Basavapathruni A, Vingerhoets J, de Béthune MP, Chung R, Bailey CM, Kim J, et al . Modulation of HIV-1 Synergistic Inhibition by Reverse Transcriptase Mutations. Biochemistry 2005; Submitted.
61. Zhu QY, Scarborough A, Polsky B, Chou TC. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. AIDS Res Hum Retroviruses 1996; 12: 507-17.
62. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 4680-6.
63. Gruzdev B, Rakhmanova A, Doubovskaya E, Yakovlev A, Peeters M, Rinehart A, et al. A randomized, double-blind, placebocontrolled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 2003; 17: 2487-2494.
64. Sankatsing SU, Weverling GJ, Peeters M, van't Klooster G, Gruzdev B, Rakhmanova A, et al. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS 2003; 17: 2623-7.
65. Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, et al. An open-label assessment of TMC 125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003; 17: F49-F54.
66. Balzarini J, Pelemans H, Aquaro S, Perno CF, Witvrouw M, Schols D, et al. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol 1996; 50: 394-401.
67. Stone A. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov 2002; 1: 977-85.
68. Fujiwara T, Sato A, El-Farrash M, Miki S, Abe K, Isaka Y, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998; 42: 1340-5.
69. Ren J, Nichols C, Bird LE, Fujiwara T, Sugimoto H, Stuart DI, et al. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J Biol Chem 2000; 275: 14316-20.
70. Loksha YM, el-Barbary AA, el-Badawi MA, Nielsen C, Pedersen EB. Synthesis of 2-(aminocarbonylmethylthio)-1H-imidazoles as novel Capravirine analogues. Bioorg Med Chem 2005; 13: 4209-20.
71. Pata JD, Stirtan WG, Goldstein SW, Steitz TA. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 2004; 101: 10548-53.
72. Wang LZ, Kenyon GL, Johnson KA. Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1. J Biol Chem 2004; 279: 38424-32.
73. Skillman AG, Maurer KW, Roe DC, Stauber MJ, Eargle D, Ewing TJ, et al. A novel mechanism for inhibition of HIV-1 reverse transcriptase. Bioorg Chem 2002; 30: 443-58.
74. Jochmans D, Kesteleyn B, Marchand B, Gotte M, Ivens T, Dehertogh P, et al. In 12th Conference on Retroviruses and Opportunistic Infections: Boston, Massachusetts, 2005.
75. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998; 282: 1669-75.
76. Abrescia N, D'Abbraccio M, Figoni M, Busto A, Maddaloni A, De Marco M. Hepatotoxicity of antiretroviral drugs. Curr Pharm Des 2005; 11(28): 3697-710.
77. Burlet S, Pietrancosta N, Laras Y, Garino C, Quelever G, Kraus JL. Prospects for the resistance to HIV protease inhibitors: current drug design approaches and perspectives. Curr Pharm Des 2005; 11(24): 3077-90.
78. Gomtsyan A, Lee CH. Nonnucleoside inhibitors of adenosine kinase. Curr Pharm Des 2004; 10(10): 1093-103.